<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03682497</url>
  </required_header>
  <id_info>
    <org_study_id>D6401C00004</org_study_id>
    <nct_id>NCT03682497</nct_id>
  </id_info>
  <brief_title>Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium</brief_title>
  <official_title>A Phase I, Open Label, Randomized, Parallel Group, Multicentre Study to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium [sK+] During 28 Days in Patients With HFmrEF or HFpEF and eGFR in the Range of ≥40 and ≤70 mL/Min/1.73m2.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, Multicentre study to Compare the Effect of AZD9977 and Spironolactone on
      Serum Potassium [sK+] during 28 days in Patients with HFmrEF or HFpEF and eGFR in the range
      of ≥40 and ≤70 mL/min/1.73m2.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Attendance at study sites carries risk of COVID-19 infection. Non-attendance at planned study
    site visits has unacceptable study related patient safety risk.
  </why_stopped>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative change (%) from baseline in serum potassium</measure>
    <time_frame>Measurements on day 1, 7, 14, 21 and 28 will be used. The primary comparison between Spironolactone and AZD9977 will be done at day 28.</time_frame>
    <description>To compare the effect of AZD9977 with spironolactone on serum potassium (sK+)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma trough concentrations (Ctrough) values of spironolactone and AZD9977</measure>
    <time_frame>PK samples will be taken (within 60 min prior to dose) at day 1, 7, 14, 21 and 28.</time_frame>
    <description>To evaluate the pharmacokinetics (PK) of AZD9977 and spironolactone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change (%) from baseline in serum potassium</measure>
    <time_frame>Measurements on day 1, 7 and 14 will be used. The primary comparison between Spironolactone and AZD9977 will be done at day 14.</time_frame>
    <description>To compare the effects of AZD9977 with spironolactone on serum potassium at Day 14.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spironolactone treatment for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD9977</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD9977 treatment for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9977</intervention_name>
    <description>AZD9977 capsules taken orally for 28 days.</description>
    <arm_group_label>AZD9977</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>Spironolactone tablets taken orally for 28 days.</description>
    <arm_group_label>Spironolactone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms and signs consistent with a diagnosis of heart failure (HF)

          -  Left ventricular ejection fraction (LVEF) ≥40% by transthoracic echocardiography
             within the past 12 months

          -  Plasma NT-proBNP level ≥125 pg/ml (≥ 600pg/mL if patient has persistent or permanent
             atrial fibrillation, atrial flutter, or atrial tachycardia)

          -  Estimated glomerular filtration rate (eGFR) ≥40 and ≤70ml/min/1.73m2 (by CKD-EPI
             formula).

          -  Baseline serum potassium (sK+) level ≥3.5 and ≤4.8mmol/l.

          -  Stable doses of the following medications at baseline for at least 4 weeks prior to
             randomisation:

        Angiotensin receptor blocker (ARB) or Angiotensin converting enzyme inhibitor (ACEi) Loop
        diuretic (up to a 120mg furosemide dose or equivalent

        Exclusion Criteria:

          -  Patients with documented LVEF &lt;40% at any time (i.e. patients with previously impaired
             LVEF that has now improved are not permitted).

          -  Patients experiencing acute decompensation of heart failure requiring hospital
             admission or escalation in therapy.

          -  Primary cardiomyopathy (e.g. constrictive, restrictive, infiltrative, toxic,
             hypertrophic, congenital or any primary cardiomyopathy in judgment of Investigator).

          -  Hyponatraemia, defined as serum Na+ &lt;135 mmol/L at the time of enrollment.

          -  Persistent resting sinus tachycardia &gt;110 bpm or sinus bradycardia &lt;45bpm.

          -  Systolic blood pressure (BP) &lt;110mmHg or &gt;180mmHg.

          -  Diastolic BP &lt;60 mmHg or &gt;100 mmHg.

          -  Patients previously intolerant to MRA (e.g. spironolactone or eplerenone) for any
             reason.

          -  Medical conditions associated with development of hyperkalaemia (e.g. Addison's
             disease).

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥2.0 times
             the upper limit of normal (ULN).

          -  Patients who have been taking an MR antagonist within 1 month prior to randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brandys nad Labem</city>
        <zip>250 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ceska Lipa</city>
        <zip>470 77</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaromer</city>
        <zip>551 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louny</city>
        <zip>440 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Legnica</city>
        <zip>59-220</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <zip>50-981</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9PQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure.</keyword>
  <keyword>Oral selective mineralocorticoid receptor modulator.</keyword>
  <keyword>Heart failure with preserved ejection fraction (HFpEF).</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

